Rizatriptan benzoate is a selective 5-hydroxytriptamine1B/1D receptor agonist that was launched in 1988 for the acute treatment of migraine in adults. Rizatriptan undergoes hepatic first pass metabolism, hence it shows poor bioavailability. The motive of the study is to formulate a buccalmucoadhesive dosage form using biocompatible polymers with rizatriptan to circumvent the first pass metabolism and to increase the bioavailability. This study was designed to develop a buccalmucoadhesive tablet containing rizatriptan benzoate using primary and secondary bioadhesive polymeric combinations such as carbopol 934 with HPMC K-4M, PVP and chitosan in different concentrations using direct compression technique. Tablets were subjected to physico-chemical parameters along with Swelling index, surface pH, bioadhesion strength, in-vitro drug release. Satisfactory results were obtained in all evaluated parameters. The drug release of all formulations follows zero order kinetics. All the prepared tablets are weighing between 144 mg to 154 mg. The thickness of the tablet was in the range of 3.5 to 3.7 mm. Hardness was in the range of 3.0 to 6.0 kg/cm2. Swelling index is in the range of 44% to 81%. Surface pH was in the range of 5.9 to 6.19. Drug content uniformity study showed drug was dispersed equally throughout the formulation and is in the range of 97.46% to 99.02%. FT-IR studies revealed that, there was no incompatibility of drug with the excipients used. Formulations F1 and F8 showed 92% drug release at 8th hr. Release of rizatriptan from all the tablets followed zero order kinetics and showed controlled release. From the current study it was concluded that rizatriptan benzoate buccal mucoadhesive tablets showed better swelling property, good bioadhesive strength, residence time and drug release to improve the bioavailability and greater therapeutic efficacy.
Loading....